[{"Assets_0_Q3_USD":695544000.0,"CommonStockSharesConverted_0_Q3_shares":121895479.0,"CommonStockSharesOutstanding_0_Q3_shares":121895479.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_3_Q3_USD":-87083000.0,"NetIncomeLossConverted_1_Q3_USD":-50735000.0,"NetIncomeLossConverted_3_Q3_USD":-123564000.0,"StockholdersEquity_0_Q3_USD":619716000.0,"EarningsPerShareBasic_1_Q3_USD":-0.5,"EarningsPerShareBasic_3_Q3_USD":-1.24,"Ticker":"ALLO","CIK":"1737287","name":"ALLOGENE THERAPEUTICS, INC.","OfficialName":"Allogene Therapeutics Inc. Common Stock","form":"10-Q","period":"20190930","fy":"2019.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1134878416.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20191105"}]